New Delhi The Drugs Controller General of India (DCGI) has recommended emergency use authorisation (EUA) for Bharat Biotech’s Covaxin for children between 6 and 12 years.
The DCGI has also recommended EUA for Corbevax (made by Biological E) for children aged 5 to 12 years and Zydus Cadila’s ZyCoV-D for those above 12 years.
Confirming the development, Union Health Minister, Mansukh Mandaviya in a tweet (in Hindi) said: “The approvals will help strengthen India’s fight against Covid-19.”
The subject expert committee (SEC) had suggested amendments to protocols for Covaxin. Among the India-made vaccines, Coaxin is the second-most predominant one after Covishield.
‘Covaxin’ is already administered to children in the age group of 15-18 years apart from adults. The vaccine is administered in two doses, with a gap of 28 days between the first and second doses.